{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:27:02Z","timestamp":1760146022852,"version":"build-2065373602"},"reference-count":55,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["CO-US-540-6139"],"award-info":[{"award-number":["CO-US-540-6139"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: The extent of the SARS-CoV-2 short-term evolution under Remdesivir (RDV) exposure and whether it varies across different upper respiratory compartments are not fully understood. Methods: Patients hospitalized for COVID-19, with or without RDV therapy, were enrolled and completed up to three visits, in which they provided specimens from four respiratory compartments. Near full-length genome SARS-CoV-2 sequences were obtained from viral RNA, standard lineage and variant assignments were performed, and viral mutations in the RNA-dependent RNA polymerase (RdRp) region\u2014the RDV target gene\u2014were detected and compared between participants with and without RDV, across the four compartments, within participants across visits, and versus a larger sequence dataset. The statistical analysis used a generalized linear mixed-effects model. Results: A total of 139 sequences were obtained from 37 out of the 44 (84%) enrolled participants. The genotyping success varied across respiratory compartments, which ranged from 42% with oropharyngeal specimens to 67% with nasopharyngeal specimens and showed improvement with higher viral loads. No RdRp mutations known to be associated with RDV resistance were identified, and for 34 detected mutations at 32 amino acid positions that are not known as RDV-associated, there was no evidence of any associations with the RDV exposure, respiratory compartment, or time. At least 1 of these 34 mutations were detected in all participants, and some differed from the larger sequence dataset. Conclusions: This study highlighted the SARS-CoV-2 short-term genomic stability within hosts and across upper respiratory compartments, which suggests a lack of evolution of RDV resistance over time. This contributes to our understanding of SARS-CoV-2 genomic dynamics.<\/jats:p>","DOI":"10.3390\/v16101511","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T08:54:13Z","timestamp":1727168053000},"page":"1511","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Limited Short-Term Evolution of SARS-CoV-2 RNA-Dependent RNA Polymerase under Remdesivir Exposure in Upper Respiratory Compartments"],"prefix":"10.3390","volume":"16","author":[{"given":"Vladimir","family":"Novitsky","sequence":"first","affiliation":[{"name":"Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curt G.","family":"Beckwith","sequence":"additional","affiliation":[{"name":"Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Carpenter-Azevedo","sequence":"additional","affiliation":[{"name":"State Health Laboratories, Rhode Island Department of Health, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-8947","authenticated-orcid":false,"given":"Jimin","family":"Shin","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Connecticut, Farmington, CT 06030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Hague","sequence":"additional","affiliation":[{"name":"Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soya","family":"Sam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Steingrimsson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Huard","sequence":"additional","affiliation":[{"name":"State Health Laboratories, Rhode Island Department of Health, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Lethbridge","sequence":"additional","affiliation":[{"name":"Rhode Island Hospital, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata","family":"Sahu","sequence":"additional","affiliation":[{"name":"The Miriam Hospital, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Rapoza","sequence":"additional","affiliation":[{"name":"The Miriam Hospital, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Chandran","sequence":"additional","affiliation":[{"name":"The Miriam Hospital, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauri","family":"Bazerman","sequence":"additional","affiliation":[{"name":"The Miriam Hospital, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Hipolito","sequence":"additional","affiliation":[{"name":"Rhode Island Hospital, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Diaz","sequence":"additional","affiliation":[{"name":"Rhode Island Hospital, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniella","family":"Carnevale","sequence":"additional","affiliation":[{"name":"Rhode Island Hospital, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"August","family":"Guang","sequence":"additional","affiliation":[{"name":"Computational Biology Core, Center for Computation and Visualization, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fizza","family":"Gillani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"},{"name":"Rhode Island Hospital, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela M.","family":"Caliendo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-1108","authenticated-orcid":false,"given":"Rami","family":"Kantor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"ref_1","unstructured":"WHO (2024, June 14). WHO Coronovirus (COVID-19) Dashboard. United States of America Situation. Available online: https:\/\/covid19.who.int\/region\/amro\/country\/us."},{"key":"ref_2","unstructured":"WHO (2024, June 14). WHO Coronovirus (COVID-19) Dashboard. Global Situation. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_3","unstructured":"(2024, June 08). CDC CDC Public Health Science Agenda for COVID-19, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-agenda-covid19.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.aivir.2016.08.008","article-title":"The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing","volume":"96","author":"Snijder","year":"2016","journal-title":"Adv. Virus Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104793","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.antiviral.2013.11.006","article-title":"SARS-CoV ORF1b-encoded nonstructural proteins 12-16: Replicative enzymes as antiviral targets","volume":"101","author":"Subissi","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2040206618764483","DOI":"10.1177\/2040206618764483","article-title":"Nucleosides for the treatment of respiratory RNA virus infections","volume":"26","author":"Jordan","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Focosi, D., Franchini, M., Maggi, F., and Shoham, S. (2024). COVID-19 therapeutics. Clin. Microbiol. Rev., 37.","DOI":"10.1128\/cmr.00119-23"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.dsx.2020.05.018","article-title":"Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir: First Approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"ref_14","unstructured":"(2024, June 08). COVID-19 Treatment Guidelines Panel Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health, Available online: https:\/\/files.covid19treatmentguidelines.nih.gov\/guidelines\/covid19treatmentguidelines.pdf."},{"key":"ref_15","unstructured":"NIH (2024, June 08). COVID-19 Treatment Guidlines. Remdesivir, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/remdesivir\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate Use of Remdesivir for Patients with Severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs. Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in Patients with Severe COVID-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e4166","DOI":"10.1093\/cid\/ciaa1041","article-title":"Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care","volume":"73","author":"Olender","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of COVID-19-Preliminary Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cegh.2020.07.011","article-title":"Remdesivir and its antiviral activity against COVID-19: A systematic review","volume":"9","author":"Frediansyah","year":"2020","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5582\/ddt.2020.01015","article-title":"Rapid review for the anti-coronavirus effect of remdesivir","volume":"14","author":"Li","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"eabo0718","DOI":"10.1126\/scitranslmed.abo0718","article-title":"Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms","volume":"14","author":"Stevens","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Szemiel, A.M., Merits, A., Orton, R.J., MacLean, O.A., Pinto, R.M., Wickenhagen, A., Lieber, G., Turnbull, M.L., Wang, S., and Furnon, W. (2021). In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009929"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e0019822","DOI":"10.1128\/aac.00198-22","article-title":"In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance","volume":"66","author":"Checkmahomed","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00221-18","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105247","DOI":"10.1016\/j.antiviral.2022.105247","article-title":"Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis","volume":"198","author":"Focosi","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mari, A., Roloff, T., Stange, M., Sogaard, K.K., Asllanaj, E., Tauriello, G., Alexander, L.T., Schweitzer, M., Leuzinger, K., and Gensch, A. (2021). Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. Microorganisms, 9.","DOI":"10.3390\/microorganisms9051094"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1762","DOI":"10.1093\/cid\/ciaa1474","article-title":"Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019","volume":"73","author":"Martinot","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yang, S., Multani, A., Garrigues, J.M., Oh, M.S., Hemarajata, P., Burleson, T., Green, N.M., Oliai, C., Gaynor, P.T., and Beaird, O.E. (2023). Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation. Microorganisms, 11.","DOI":"10.3390\/microorganisms11082096"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/cid\/ciac769","article-title":"Remdesivir Resistance in Transplant Recipients With Persistent Coronavirus Disease 2019","volume":"76","author":"Hogan","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e28877","DOI":"10.1002\/jmv.28877","article-title":"SARS-CoV-2 intrahost evolution in immunocompromised patients in comparison with immunocompetent populations after treatment","volume":"95","author":"Ahmadi","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100735","DOI":"10.1016\/j.xcrm.2022.100735","article-title":"Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection","volume":"3","author":"Heyer","year":"2022","journal-title":"Cell Rep. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e13179","DOI":"10.1111\/irv.13179","article-title":"Use of whole genome sequencing to identify low-frequency mutations in SARS-CoV-2 patients treated with remdesivir","volume":"17","author":"Nirmalarajah","year":"2023","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/infdis\/jiad270","article-title":"Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)","volume":"228","author":"Hedskog","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"DNA Pipelines R&D, Farr, B., Rajan, D., Dawson, E., Shirley, L., Quail, M., Park, N., Redshaw, N., Bronner, I.F., and Aigrain, L. (2021, February 05). COVID-19 ARTIC v3 Illumina Library Construction and Sequencing Protocol V.5. Available online: https:\/\/www.protocols.io\/view\/covid-19-artic-v3-illumina-library-construction-an-j8nlke665l5r\/v5.","DOI":"10.17504\/protocols.io.bibtkann"},{"key":"ref_40","unstructured":"(2023, June 06). Centre for Genomic Pathogen Surveillance Pangolin: Phylogenetic Assignment of Named Global Outbreak LINeages. Available online: https:\/\/github.com\/cov-lineages\/pangolin."},{"key":"ref_41","unstructured":"(2023, June 06). Nextstrain Project Nextclade: Clade Assignment, Mutation Calling, and Sequence Quality Checks. Available online: https:\/\/clades.nextstrain.org\/."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.21105\/joss.03773","article-title":"Nextclade: Clade assignment, mutation calling and quality control for viral genomes","volume":"6","author":"Aksamentov","year":"2021","journal-title":"J. Open Source Softw."},{"key":"ref_43","unstructured":"(2023, June 06). A Stanford HIVDB Team Website Stanford University Coronovirus Aniviral & Resistance Database. Available online: https:\/\/covdb.stanford.edu\/drms\/rdrp\/."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.medj.2023.08.001","article-title":"Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2","volume":"4","author":"Hirotsu","year":"2023","journal-title":"Med"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"ref_46","unstructured":"GISAID (2024, May 24). Global Initiative on Sharing All Influenza Data (GISAID) Repository. Available online: https:\/\/www.epicov.org."},{"key":"ref_47","unstructured":"Carstensen, B., Plummer, M., Laara, E., and Hills, M. (2024, June 10). Epi: Statistical Analysis in Epidemiology. Available online: https:\/\/cran.r-project.org\/web\/packages\/Epi\/index.html."},{"key":"ref_48","unstructured":"R Core Team (2023, May 19). The R Project for Statistical Computing. Available online: http:\/\/www.R-project.org\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.cmi.2022.05.005","article-title":"Combine, Immunocompromised patients have been neglected in COVID-19 trials: A call for action","volume":"28","author":"Troseid","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Majchrzak, M., Madej, L., Lysek-Gladysinska, M., Zarebska-Michaluk, D., Zegadlo, K., Dziuba, A., Nogal-Nowak, K., Kondziolka, W., Sufin, I., and Myszona-Tarnowska, M. (2024). The RdRp genotyping of SARS-CoV-2 isolated from patients with different clinical spectrum of COVID-19. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09146-x"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Maurya, R., Mishra, P., Swaminathan, A., Ravi, V., Saifi, S., Kanakan, A., Mehta, P., Devi, P., Praveen, S., and Budhiraja, S. (2022). SARS-CoV-2 Mutations and COVID-19 Clinical Outcome: Mutation Global Frequency Dynamics and Structural Modulation Hold the Key. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.868414"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"110466","DOI":"10.1016\/j.ygeno.2022.110466","article-title":"SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength?","volume":"114","author":"Saifi","year":"2022","journal-title":"Genomics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40121-023-00772-7","article-title":"Systematic Review on the Correlation Between SARS-CoV-2 Real-Time PCR Cycle Threshold Values and Epidemiological Trends","volume":"12","author":"Sala","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"ofac463","DOI":"10.1093\/ofid\/ofac463","article-title":"Correlation of SARS-CoV-2 Nasopharyngeal CT Values With Viremia and Mortality in Adults Hospitalized With COVID-19","volume":"9","author":"Hagman","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ijid.2022.07.022","article-title":"Ct values as a diagnostic tool for monitoring SARS-CoV-2 viral load using the QIAstat-Dx(R) Respiratory SARS-CoV-2 Panel","volume":"122","author":"Penarrubia","year":"2022","journal-title":"Int. J. Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/10\/1511\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:01:36Z","timestamp":1760112096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/10\/1511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["v16101511"],"URL":"https:\/\/doi.org\/10.3390\/v16101511","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}